View in EDS HTML Full Text PDF Full Text

Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.

Saved in:
Bibliographic Details
Title: Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Authors: Das S; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Ciombor KK; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Haraldsdottir S; Divisions of Medical Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Pumpalova Y; Division of Hospital Medicine, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Sahin IH; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA., Pineda G; Divisions of Medical Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Shyr Y; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Lin EP; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Big Data Research Center, Fu Jen Catholic University, Taipei, Taiwan., Hsu CY; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Chu SK; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Goff LW; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Cardin DB; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Bilen MA; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA., Fisher GA; Divisions of Medical Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Wu C; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA., Berlin J; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Source: The oncologist [Oncologist] 2020 Aug; Vol. 25 (8), pp. 669-679. Date of Electronic Publication: 2020 Jan 14.
Publication Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 31943525
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Das+S%22">Das S</searchLink>; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Ciombor+KK%22">Ciombor KK</searchLink>; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Haraldsdottir+S%22">Haraldsdottir S</searchLink>; Divisions of Medical Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Pumpalova+Y%22">Pumpalova Y</searchLink>; Division of Hospital Medicine, Department of Medicine, Stanford University Medical Center, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Sahin+IH%22">Sahin IH</searchLink>; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.<br /><searchLink fieldCode="AU" term="%22Pineda+G%22">Pineda G</searchLink>; Divisions of Medical Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Shyr+Y%22">Shyr Y</searchLink>; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Lin+EP%22">Lin EP</searchLink>; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Big Data Research Center, Fu Jen Catholic University, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Hsu+CY%22">Hsu CY</searchLink>; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Chu+SK%22">Chu SK</searchLink>; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Goff+LW%22">Goff LW</searchLink>; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Cardin+DB%22">Cardin DB</searchLink>; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Bilen+MA%22">Bilen MA</searchLink>; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.<br /><searchLink fieldCode="AU" term="%22Fisher+GA%22">Fisher GA</searchLink>; Divisions of Medical Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Wu+C%22">Wu C</searchLink>; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.<br /><searchLink fieldCode="AU" term="%22Berlin+J%22">Berlin J</searchLink>; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2020 Aug; Vol. 25 (8), pp. 669-679. <i>Date of Electronic Publication: </i>2020 Jan 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31943525
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1634/theoncologist.2019-0637
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 669
    Titles:
      – TitleFull: Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Das S
      – PersonEntity:
          Name:
            NameFull: Ciombor KK
      – PersonEntity:
          Name:
            NameFull: Haraldsdottir S
      – PersonEntity:
          Name:
            NameFull: Pumpalova Y
      – PersonEntity:
          Name:
            NameFull: Sahin IH
      – PersonEntity:
          Name:
            NameFull: Pineda G
      – PersonEntity:
          Name:
            NameFull: Shyr Y
      – PersonEntity:
          Name:
            NameFull: Lin EP
      – PersonEntity:
          Name:
            NameFull: Hsu CY
      – PersonEntity:
          Name:
            NameFull: Chu SK
      – PersonEntity:
          Name:
            NameFull: Goff LW
      – PersonEntity:
          Name:
            NameFull: Cardin DB
      – PersonEntity:
          Name:
            NameFull: Bilen MA
      – PersonEntity:
          Name:
            NameFull: Fisher GA
      – PersonEntity:
          Name:
            NameFull: Wu C
      – PersonEntity:
          Name:
            NameFull: Berlin J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2020 Aug
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1549-490X
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: The oncologist
              Type: main
ResultId 1